Genelux (GNLX) to Release Quarterly Earnings on Monday

Genelux (NASDAQ:GNLX) is expected to be announcing its results before the market opens on Monday, April 6th. Analysts expect the company to announce earnings of ($0.22) per share for the quarter.

Genelux (NASDAQ:GNLX) last announced its earnings results on Thursday, March 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.01 million during the quarter. On average, analysts expect Genelux to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Genelux Price Performance

Shares of GNLX stock opened at $2.48 on Monday. The firm has a market cap of $111.13 million, a P/E ratio of -2.88 and a beta of 0.15. The firm has a fifty day moving average of $2.67 and a two-hundred day moving average of $4.12. Genelux has a 1-year low of $1.99 and a 1-year high of $8.53.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on GNLX shares. Wall Street Zen raised Genelux from a “sell” rating to a “hold” rating in a report on Saturday, March 21st. Weiss Ratings restated a “sell (e+)” rating on shares of Genelux in a research note on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating on shares of Genelux in a research note on Monday, January 5th. Finally, Benchmark dropped their target price on shares of Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a report on Friday, March 20th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $20.40.

Insider Transactions at Genelux

In related news, Director John Thomas sold 10,000 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $2.90, for a total transaction of $29,000.00. Following the completion of the transaction, the director directly owned 482,784 shares in the company, valued at $1,400,073.60. This represents a 2.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 8.80% of the stock is owned by corporate insiders.

Institutional Trading of Genelux

Hedge funds have recently added to or reduced their stakes in the business. Creative Planning raised its position in Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after acquiring an additional 2,084 shares in the last quarter. Raymond James Financial Inc. grew its stake in shares of Genelux by 22.6% in the 2nd quarter. Raymond James Financial Inc. now owns 28,933 shares of the company’s stock worth $83,000 after purchasing an additional 5,333 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Genelux by 1.8% in the 2nd quarter. Geode Capital Management LLC now owns 318,825 shares of the company’s stock worth $915,000 after purchasing an additional 5,596 shares in the last quarter. Squarepoint Ops LLC bought a new stake in shares of Genelux in the 4th quarter worth approximately $52,000. Finally, Qube Research & Technologies Ltd lifted its stake in Genelux by 101.3% during the third quarter. Qube Research & Technologies Ltd now owns 37,224 shares of the company’s stock valued at $156,000 after purchasing an additional 18,734 shares during the last quarter. Institutional investors own 37.33% of the company’s stock.

About Genelux

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.